| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.0016 | 1 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.0065 | 1 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.00097 | 1 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.0059 | 1 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.00091 | 1 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | 0.00083 | 1 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.00076 | 1 |